ALX ONCOLOGY HOLDINGS INC

ALX ONCOLOGY HOLDINGS INC insiders are currently net buyers of ALXO stock, showing neutral sentiment over the past 90 days. Executives have purchased $86.7M while selling $41.8M, resulting in a positive net flow of $45.0M. This buying activity represents 67% of total transaction volume.

ALX ONCOLOGY HOLDINGS INC has 17 active insiders who have filed SEC Form 4 transactions in the past 90 days. G. Walmsley Graham (Executive) leads with 3 transactions totaling $20.0M. Opportunity Fund, L.p. Vivo (Executive) follows with 3 transactions worth $18.5M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. ALX ONCOLOGY HOLDINGS INC's current score of 67/100 indicates neutral insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $86.7M in purchases versus $41.8M in sales.

The most recent insider transaction occurred on Feb 17, 2026, when Lettmann Jason (Executive) disposed of 2,201 shares at $2.27 per share for $5.0K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, ALXO insider trading sentiment is currently neutral with an Alignment Score of 67/100. The net insider flow of $45.0M reflects accumulation, with 67% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like ALX ONCOLOGY HOLDINGS INC. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At ALXO, we track all Form 4 filings—currently showing 275 transactions from 17 insiders over 90 days.

A 10b5-1 plan allows ALX ONCOLOGY HOLDINGS INC executives to pre-schedule stock sales when they don't possess material non-public information. At ALXO, approximately 30% of recent transactions are 10b5-1 trades. The remaining 70% are discretionary trades, which may carry more informational value.

You can monitor ALX ONCOLOGY HOLDINGS INC (ALXO) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 17 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. ALX ONCOLOGY HOLDINGS INC's current score of 67/100 indicates moderately bullish sentiment suggesting insider confidence. This is calculated from $86.7M in purchases versus $41.8M in sales over 90 days, resulting in a net flow of $45.0M.

SEC Form 4 filings are mandatory reports that ALX ONCOLOGY HOLDINGS INC insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At ALXO, the most common type is "S" with 19 occurrences. The most recent Form 4 was filed on Feb 17, 2026 by Lettmann Jason.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At ALX ONCOLOGY HOLDINGS INC, approximately 30% of recent transactions are executed under 10b5-1 plans, while 70% appear to be discretionary trades. This mix provides a balanced picture—some planned, others reflecting real-time decisions.